04.18.18

Data from BioTime’s OpRegen and Retinal Restoration Programs to Be Presented at ARVO 2018

Source: BioTime

BioTime announced that data from the ongoing OpRegen clinical trial and Retinal Restoration program will be presented at the upcoming Association for Research in Vision and Ophthalmology (ARVO) meeting taking place from April 29 – May 3, 2018, in Honolulu, Hawaii.

The scheduled times (noted in local Hawaii time) and location of the BioTime data presentations at the Hawaii Convention Center are as follows:

OpRegen Poster Presentation

  • Title: Phase I/IIa Clinical Trial of Human Embryonic Stem Cell (hESC)-Derived Retinal Pigmented Epithelium (RPE, OpRegen) Transplantation in Advanced Dry Form Age-Related Macular Degeneration (AMD): Interim Results
  • Presentation Number – Posterboard Number: 77-A0124
  • Session Title: AMD and Retinal Therapies Excluding Anti-VEGF
  • Date/Time: April 29, 2018 from 8:15am – 10:00am

ARVO Minisymposium – The nuts and bolts of novel drug development

  • Title: Derivation of RPE cells from human embryonic stem cells: The journey from basic research to clinical application
  • Presentation Number: 2582
  • Date/Time: May 1, 2018 from 8:56am – 9:14am

Retinal Restoration Paper Presentation

  • Title: Transplantation of laboratory-grown human retinal tissue in the subretinal space of the cat eye
  • Presentation Number: 2986
  • Session Title: Retinal Gene Therapy and Stem Cell Transplantation
  • Date/Time: May 1, 2018 from 12:15pm – 12:30pm

As a reminder, BioTime’s Retinal Restoration program is based on the ability to generate 3-dimensional human retinal tissue derived from human pluripotent cells. The company’s 3-dimensional retinal tissue technology may address the unmet need of implementing a retinal restoration strategy to address severe retinal degenerative diseases. In 2017, the Small Business Innovation Research program of the National Institutes of Health awarded BioTime a grant of up to $1.56 million to further develop this innovative, next generation retinal restoration program.

Related Content